Physician profile
Robert M Blum
NPI 1386634897
$2,060.07
in general payments reported to CMS, 2019-2025
22 companies · $241 in 2025
The $241 reported for 2025 was more than what 79% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $454 · 2020: $106 · 2021: $207 · 2022: $292 · 2023: $418 · 2024: $343 · 2025: $241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,001.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,001.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $414.10 | 2019-2025 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $246.12 | 2019-2023 | Jornay Pm |
| Corium, LLC | $216.90 | 2022-2025 | Azstarys |
| Merck Sharp & Dohme LLC | $192.83 | 2019-2024 | M-M-R II, Gardasil 9, Vaxneuvance |
| Cranial Technologies, INC | $169.72 | 2019-2025 | Doc Band |
| Pfizer INC. | $160.78 | 2019-2021 | |
| Alk-Abello, INC | $111.57 | 2023-2025 | Odactra, Ragwitek, Grastek |
| Sanofi Pasteur INC. | $99.44 | 2021-2024 | |
| Kaleo, INC. | $61.89 | 2019-2023 | Auvi-Q |
| Takeda Pharmaceuticals U.S.A., INC. | $48.84 | 2019-2025 | Elaprase |
| Gilead Sciences, INC. | $47.26 | 2024-2025 | Yescarta |
| Verrica Pharmaceuticals INC. | $40.95 | 2023-2024 | Ycanth |
| Collegium Pharmaceutical, INC. | $40.51 | 2025 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $34.07 | 2021 | |
| Seqirus USA INC | $33.78 | 2022-2023 | Flucelvax Quadrivalent |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $29.10 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $23.53 | 2025 | Dojolvi |
| Biomarin Pharmaceutical INC. | $23.37 | 2024 | Voxzogo 1.2mg |
| Sobi, INC | $21.36 | 2019 | |
| Glaxosmithkline, LLC. | $17.02 | 2023 | Bexsero |
| Alexion Pharmaceuticals, INC. | $14.02 | 2024 | Koselugo |
| Aimmune Therapeutics, INC. | $12.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Blum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.